Eligibility of the Systolic Blood Pressure Intervention Trial (SPRINT)‎ to the Chinese Adults

Abstract EN

Objective.

To explore the proportion and characteristic of Chinese adults meeting The Systolic Blood Pressure Intervention Trial (SPRINT) eligibility criteria and assess its generalizability.

Method.

Our study was based on a cross-sectional, population-based survey with a sample of 26,093 participants aged over 20 years.

The SPRINT eligibility criteria were age≥50 years, elevated SBP of 130 to 180 mmHg depending on the number of antihypertensive medication classes being taken, and increased cardiovascular disease (CVD) but without diabetes, history of stroke and estimated glomerular filtration rate<20 ml/min/1.73 m2, or receiving dialysis.

Results.

Overall, we estimated that 4,036 (15.5%) participants would meet the SPRINT eligibility criteria.

They were generally older, likely to be female, lower educational level, tended to be more overweight, and had higher Framingham risk score compared with overall population or subjects aged≥50 years.

Of participants eligible for SPRINT, most (56.2%) of them were not treated for hypertension, and 542 (13.4%) were not previously considered to have hypertension or need for antihypertension therapy.

Among the 11,637 adults with hypertension, 3,494 (30.0%) would potentially benefit from treatment intensification.

The most common antihypertensive medication class being taken was diuretic agents.

Conclusion.

A substantial percentage of Chinese subjects meet the SPRINT eligibility criteria.

Further studies are needed to assess the cost-effectiveness from treatment intensification in Chinese setting.